Skip to main content
The Evidence Base Post

Truveta launches Truveta Intelligence to deliver AI-powered, real-time insights from real-world data

  • Katie McCool
Doctor uses a tablet displaying holographic DNA strands, charts, and AI icons on a transparent digital interface.

Truveta has introduced Truveta Intelligence, a new platform designed to enable faster analysis of continuously updated real-world data (RWD) and support more timely healthcare and research decision-making.

Developed to address delays commonly associated with traditional evidence generation, the platform aims to reduce the time required to translate large volumes of healthcare data into actionable insights. The company stated that the system is intended to help healthcare organizations, life sciences teams, and public health authorities evaluate how patient populations, treatments, and outcomes are evolving in routine clinical care.

The system is built on Truveta Data, a longitudinal dataset representing care from more than 130 million patients across multiple therapeutic areas and care settings. These data are continuously refreshed using electronic health records (EHRs) from Truveta’s member health systems, enabling analyses that reflect current clinical practice rather than relying on static or historical datasets. Queries are translated into structured analyses, with results designed to be fully inspectable so that users can review the underlying data, code sets, and methodology used to generate findings.

According to the company, many organizations continue to face challenges when trying to understand what is happening in real-world care settings. While generative AI tools have improved the ability to summarize guidelines and published literature, answering questions about how therapies perform across diverse populations or how treatment patterns change over time often requires lengthy retrospective analysis. These delays can limit the ability of healthcare and research teams to respond quickly to emerging trends in care and outcomes.

Terry Myerson, CEO and co-founder of Truveta, described the platform as addressing this time constraint, noting:

"Once our partners have a complete view of care, the next constraint is time. Many important questions go unanswered today, not because the data don't exist, but because turning data into trusted evidence takes too long. Truveta Intelligence changes that. It lets our member health systems and life sciences partners learn from how care is being delivered across the country, in real time, and act on what is true today."

The company reported that the platform allows users to pose questions in natural language about patients, treatments, and outcomes, with analyses returned in minutes. This capability may support a range of activities across research and healthcare operations. For example, real-world evidence (RWE) teams may use the tool to evaluate how therapies perform across broader patient populations, including those underrepresented in clinical trials. Healthcare leaders may also examine variation in care across sites, such as differences in post-surgical infection rates or hospital readmissions, helping to identify areas where quality improvement initiatives may have the greatest potential impact.

Johnathan Lancaster, President and Chief Scientific Officer at Truveta, highlighted the value of large-scale datasets in extending clinical insight beyond individual experience, explaining:

"A physician's personal experience, however long the career, covers thousands of patients, and within that, perhaps a handful who truly resemble any one patient. Truveta Intelligence makes visible what no individual clinician, and no single trial, could ever see alone."

Truveta Intelligence forms part of a broader ecosystem linking Truveta Data with Truveta Evidence, supporting progression from exploratory analyses to more formal evidence development. This connection is intended to help organizations move more efficiently from initial questions to validated findings that can inform research strategies, regulatory submissions, and healthcare delivery decisions.

Michael Simonov, Senior Vice President of Product at Truveta, highlighted that the platform is designed to balance speed with methodological transparency, stating:

"The value of Truveta Intelligence is not just speed. It’s the ability to ask better questions and answer them against real-world care as it evolves. Teams can explore patient populations, understand outcomes, and validate findings in minutes, all with full transparency." 

Register for free today to become a member of The Evidence Base and receive the latest news straight to your inbox.